List of companies in Re.Mind Capital's investment portfolio
Name | Description | Industry | Official Website | Location | ||
|---|---|---|---|---|---|---|
TRIPP is a digital wellness company that produces a VR meditation app. | ||||||
Delix Therapeutics is a CNS-focused drug discovery company. | ||||||
Neurocare is a mental health platform founded in 2015 by Tom Mechtersheimer . | ||||||
Developer of a computer-brain-interface platform intended to transmit information to the brain. The company's platform augments the programming of neuromodulation systems such as implants that are placed into the brain or spinal cord, enabling patients with neurological disorders or sensory deficits to access new opportunities to adapt and improve. | ||||||
Rejuveron Life Sciences is a fully integrated biotechnology platform company that invests in people and ideas to develop therapies. | ||||||
Operator of drug discovery platform intended to develop novel FDA-approved psychoactive medicines. The company's platform leverages plant derived compounds to accelerate the development of novel therapeutics, enabling physicians with the treatment and prevention of psychiatric and neurological disorders. | ||||||
OccamzRazor is an artificial Intelligence company founded in 2015 by Katharina Sophia Volz. | ||||||
Developer of bio-photonics and artificial intelligence technology designed to stratify patients for clinical trials. The company's technology uses a non-invasive, portable, inexpensive system to screen for Alzheimer's and other neurodegenerative diseases. | ||||||
Developer of a digital mental health platform intended to improve mental health through objective measurement and personalized intervention. The company's platform offers scalable, passive, and continuous remote patient monitoring and digital therapeutics for behavioral health. | ||||||
OpenBCI is an open-source brain-computer interface platform founded in 2014 by Conor Russomanno. | ||||||
Developer of a clinical-stage biotechnology company designed to pioneer precision medicines for brain diseases through the integration of data science and neuroscience. The company offers a precision neuroscience platform that cuts through brain disease heterogeneity to match the right patient populations to targeted therapeutics. | ||||||
Alto Neuroscience is engaged in psychiatric drug development which matches the right patient with the right Alto drug based on AI-derived brain biomarkers. | ||||||
Developer of a healthcare application designed to serve people to overcome social anxiety. The company's application uses a novel approach that combines evidence-based therapy with neuroscience to overcome the limitations of the mainstream, enabling users to manage their stress and break free from anxiety. |
